CVS Health Corporation $CVS Position Reduced by Carret Asset Management LLC

Carret Asset Management LLC lowered its stake in CVS Health Corporation (NYSE:CVS) by 25.6% in the 4th quarter, according to its most recent filing with the SEC. The fund owned 18,768 shares of the pharmacy operator’s stock after selling 6,469 shares during the period. Carret Asset Management LLC’s holdings in CVS Health were worth $1,489,000 as of its most recent SEC filing.

Several other large investors have also modified their holdings of CVS. Polar Capital Holdings Plc bought a new position in CVS Health during the 4th quarter worth approximately $29,441,000. Rakuten Investment Management Inc. lifted its stake in CVS Health by 310.1% during the fourth quarter. Rakuten Investment Management Inc. now owns 166,946 shares of the pharmacy operator’s stock worth $13,359,000 after purchasing an additional 126,242 shares during the last quarter. 71 West Capital Partners acquired a new position in CVS Health in the fourth quarter worth $278,000. Vanguard Personalized Indexing Management LLC boosted its holdings in CVS Health by 2.0% in the fourth quarter. Vanguard Personalized Indexing Management LLC now owns 158,284 shares of the pharmacy operator’s stock worth $12,561,000 after purchasing an additional 3,038 shares during the period. Finally, Resources Management Corp CT ADV increased its stake in CVS Health by 1,443.0% during the fourth quarter. Resources Management Corp CT ADV now owns 33,945 shares of the pharmacy operator’s stock valued at $2,694,000 after purchasing an additional 31,745 shares during the last quarter. Institutional investors own 80.66% of the company’s stock.

More CVS Health News

Here are the key news stories impacting CVS Health this week:

• Positive Sentiment: Multiple articles highlight CVS as a value opportunity, with commentary that its comeback may be “just getting started” and that the stock still looks cheap relative to its earnings and growth prospects. CVS Health’s Comeback Is Just Getting Started — and Its Valuation Still Looks Shockingly Cheap
• Positive Sentiment: Analyst sentiment remains constructive: Mizuho reportedly raised its price target on CVS due to a more stable policy environment, and Morgan Stanley previously lifted its recommendation to $111 while keeping an Overweight view. Mizuho Raises CVS Health (CVS) Price Target on More Stable Policy Environment
• Positive Sentiment: CVS continues to show operational progress, including Aetna’s AI-driven claims tools that reduced processing time by more than 20%, which could support margins and improve customer experience over time. Is CVS Health (CVS) One of Billionaire Larry Robbins’ 10 Dividend Stock Picks?
• Neutral Sentiment: Aetna also announced $130,000 in donations to Kansas City organizations, reinforcing CVS’s community-health positioning, though this is unlikely to move the stock meaningfully on its own. Aetna Donates $130,000 to Kansas City Organizations To Support Nutrition, Mental Health, Maternal Health and Health-Related Social Needs
• Neutral Sentiment: Other coverage, including Zacks and broader “CVS trending” articles, mainly reflects ongoing investor attention rather than a new fundamental catalyst. Zacks.com featured highlights include StoneCo, USANA Health, Strategic Education, Nexa Resources and CVS
• Negative Sentiment: A report on state officials revising the expense outlook for the Mass General Brigham–CVS deal may add some uncertainty around the transaction’s economics, though the market impact appears limited so far. State officials tweak expense outlook on Mass General Brigham, CVS deal

Analyst Upgrades and Downgrades

A number of research firms have recently issued reports on CVS. Cantor Fitzgerald restated an “overweight” rating on shares of CVS Health in a research report on Thursday, June 11th. Truist Financial increased their price objective on shares of CVS Health from $102.00 to $108.00 and gave the stock a “buy” rating in a research note on Monday, June 1st. Royal Bank Of Canada raised their target price on shares of CVS Health from $93.00 to $107.00 and gave the stock an “outperform” rating in a report on Thursday, May 7th. UBS Group lifted their target price on CVS Health from $100.00 to $115.00 and gave the company a “buy” rating in a research note on Monday, June 8th. Finally, Wall Street Zen cut CVS Health from a “buy” rating to a “hold” rating in a research report on Saturday. Twenty-two investment analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $100.68.

CVS Health Stock Up 0.0%

CVS stock opened at $100.71 on Wednesday. The stock has a market cap of $128.50 billion, a PE ratio of 44.37, a price-to-earnings-growth ratio of 0.99 and a beta of 0.62. The firm’s 50-day simple moving average is $88.00 and its 200 day simple moving average is $81.10. CVS Health Corporation has a fifty-two week low of $58.50 and a fifty-two week high of $102.77. The company has a quick ratio of 0.66, a current ratio of 0.87 and a debt-to-equity ratio of 0.78.

CVS Health (NYSE:CVS) last posted its earnings results on Wednesday, May 6th. The pharmacy operator reported $2.57 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.21 by $0.36. CVS Health had a net margin of 0.72% and a return on equity of 11.88%. The firm had revenue of $100.43 billion during the quarter, compared to analyst estimates of $94.99 billion. During the same period in the previous year, the business posted $2.25 EPS. CVS Health’s revenue was up 6.2% on a year-over-year basis. CVS Health has set its FY 2026 guidance at 7.300-7.500 EPS. As a group, sell-side analysts predict that CVS Health Corporation will post 7.44 EPS for the current year.

Insider Activity at CVS Health

In related news, EVP Tilak Mandadi sold 69,551 shares of the stock in a transaction that occurred on Friday, May 8th. The stock was sold at an average price of $89.58, for a total value of $6,230,378.58. Following the completion of the transaction, the executive vice president directly owned 10,133 shares of the company’s stock, valued at $907,714.14. This represents a 87.28% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, Director Larry Robbins sold 1,983,538 shares of the firm’s stock in a transaction that occurred on Tuesday, May 19th. The shares were sold at an average price of $94.45, for a total value of $187,345,164.10. Following the completion of the sale, the director owned 6,213,261 shares in the company, valued at approximately $586,842,501.45. This represents a 24.20% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last quarter, insiders have sold 3,441,551 shares of company stock valued at $323,703,977. Insiders own 0.85% of the company’s stock.

CVS Health Profile

CVS Health Corporation is a diversified healthcare company that operates a large network of retail pharmacies, pharmacy benefit management services and health care solutions. Headquartered in Woonsocket, Rhode Island, the company traces its roots to the early 1960s and has grown into an integrated provider of prescription drugs, over?the?counter products, clinical services and health insurance offerings. Its operating model combines retail pharmacy locations and in?store clinics with broader pharmacy and health plan capabilities.

Key business activities include CVS Pharmacy retail operations, MinuteClinic walk?in medical clinics and HealthHUB locations that offer expanded clinical services.